The Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its negative opinion on the marketing authorization application for intravitreal pegcetacoplan for geographic atrophy.
As Healio previously reported, Apellis Pharmaceuticals received a negative opinion for the treatment in June and sought reexamination. The company remains committed to expanding access to pegcetacoplan despite the ruling, Cedric Francois, MD, PhD, CEO and co-founder of Apellis, said in a press release.
“We are deeply disappointed by this outcome, which leaves millions of